SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Deutsche Bank Cuts Spyre Therapeutics Price Target to $123, Keeps Buy Rating

Deutsche Bank lowered its price target for Spyre Therapeutics to $123 from $127 while maintaining a Buy rating.

SYRE

Related stories